Abstract
The mortality rate of patients on extracorporeal membrane oxygenation (ECMO), especially those patients that develop acute kidney injury (AKI) is high. Acute kidney disease (AKD) is a term used to describe the continuum from AKI to chronic kidney disease. However, the role of AKD in predicting the prognosis of patients on ECMO support is unclear. A total of 168 patients who received ECMO support and survived for more than 7 days at a single hospital from 2003 to 2008 were enrolled for this study and followed up for 10 years or till mortality. Kaplan-Meier analysis and Cox proportional hazards model were used to determine the prognostic factors associated with survival. The median survival times of patients with stage 0, stage 1, stage 2 and stage 3 AKD were ≥ 10 years, 43.9 months, 1 month, and half a month, respectively. There were statistically significant differences in cumulative survival rate between patients with stage 3 AKD and those with stage 0, 1, and 2 AKD (Cox-Mantel log rank test, p<0.001, p<0.001, p = 0.023), and between patients with stage 0 AKD and those with stage 1 and 2 AKD (Cox-Mantel log rank test, p = 0.012, p<0.001). Cox regression analysis revealed that AKD stage (hazard ratio [HR]: 2.576, 95% confidential interval [CI]: 1.268-5.234, p = 0.009 for stage 1; HR: 2.349; 95% CI: 1.101-5.512, p = 0.029 for stage 2; HR: 5.252; 95% CI: 2.715-10.163, p<0.001 for stage 3) was significant independent predictor of survival. AKD stage is an independent predictor of survival in patients on ECMO support.
Highlights
Extracorporeal membrane oxygenation (ECMO) is often used for critically ill patients with respiratory and cardiac failure, and it may reduce the risk of progressive organ dysfunction
Cox regression analysis revealed that Acute kidney disease (AKD) stage was significant independent predictor of survival
AKD stage is an independent predictor of survival in patients on ECMO support
Summary
Extracorporeal membrane oxygenation (ECMO) is often used for critically ill patients with respiratory and cardiac failure, and it may reduce the risk of progressive organ dysfunction. It can be used as a bridge-to-recovery, bridge-to-transplant, or bridge-to-decision. The in-hospital mortality rate of patients on ECMO supports is high at 21%-58% depending on the indications for the intervention [1,2,3,4,5,6]. The mortality rate of patients on extracorporeal membrane oxygenation (ECMO), especially those patients that develop acute kidney injury (AKI) is high. The role of AKD in predicting the prognosis of patients on ECMO support is unclear
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
